View Older Stories View More Recent Stories

Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Jan 28, 2020 04:08PM Akcea Therapeutics (AKCA) and Ionis (IONS) report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 22, 2020 07:08AM Ionis Pharmaceuticals (IONS), Akcea Therapeutics (AKCA) Announce Positive Topline Phase 2 Results of AKCEA-APOCIII-L Rx
Jan 22, 2020 07:05AM Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020 07:04AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Report Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 2, 2020 08:01AM Akcea Therapeutics (AKCA) Reports Publication of Results from Phase 2 Study of AKCEA-APO(a)-LRx
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 16, 2019 07:09AM Akcea Therapeutics (AKCA) Announces Lynne Parshall, J.D. as Bpard Chair; Appoints Barbara Yanni to Board
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 4, 2019 07:04AM Akcea Therapeutics (AKCA) Announces Alex Howarth to Board
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Nov 25, 2019 07:19AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Commence NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 6, 2019 07:00AM Ionis provides third quarter financial results and improved 2019 guidance
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 7, 2019 06:51AM Akcea Therapeutics (AKCA), Pfizer (PFE) Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Sep 23, 2019 07:12AM Akcea Therapeutics (AKCA) Reports Election of Michael J. Yang and Joseph ‘Skip’ Klein III to Board
Sep 23, 2019 07:08AM Akcea Therapeutics (AKCA) announces departures of CEO Paula Soteropoulos, President Sarah Boyce. and COO Jeff Goldberg
Sep 23, 2019 07:00AM Akcea Announces CEO Transition and Elects Two New Board Members
Sep 23, 2019 07:00AM Akcea Announces CEO Transition and Elects Two New Board Members
Sep 16, 2019 07:02AM Akcea Therapeutics (AKCA) Reports Positive Phase 1 Results of AKCEA-TTR-LRx
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
View More Recent Stories View Older Stories